Equity Overview
Price & Market Data
Price: $0.355
Daily Change: -$0.0244 / 6.87%
Range: $0.339 - $0.393
Market Cap: $62,875,072
Volume: 1,912,699
Performance Metrics
1 Week: 18.26%
1 Month: 10.70%
3 Months: -54.63%
6 Months: -77.73%
1 Year: -74.98%
YTD: -56.28%
Company Details
Employees: 25
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.